Clinical trial
Cell Therapy for High Risk T-cell Malignancies Using CD7-Specific CAR Expressed on Non-Edited T Cells (CRIMSON-NE)
NCT03690011 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Cell Therapy for High Risk T-cell Malignancies Using CD7-Specific CAR Expressed on Non-Edited T Cells (CRIMSON-NE)
- Lead sponsor
- Baylor College of Medicine
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- August 2, 2021
- Completion date
- March 31, 2041
- Enrollment
- 45 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
t-cell acute lymphoblastic leukemia, t-cell acute lymphoblastic lymphoma, t-non-hodgkin lymphoma